Mabwell Bio-Tech (688062.SH): Earth-Shu Monoclonal Antibody Injection Receives Market Approval in Pakistan.

Maiwe Biotech (688062.SH) announced recently that the company has received notification from their cooperating client, The Searle Company Limited, that their two anti-TNF monoclonal antibody injections, 9MW0311 and 9MW0321 (sold domestically as Mileshu and Maiweijian), have obtained registration approval from the Drug Regulatory Authority of Pakistan (DRAP). Pakistan is an important country along the "Belt and Road" initiative, with a population of 240 million and increasing demand for pharmaceuticals, presenting vast market potential. It is one of the emerging markets where the company is focusing on. This marks the first time that DRAP has approved an anti-TNF monoclonal antibody biosimilar drug, and it is also the company's first product to receive overseas registration approval. The approval of the anti-TNF monoclonal antibody injections for market entry in Pakistan is another milestone in Maiwe Biotech's global commercialization strategy, bringing positive impact on the company's continuous expansion into emerging markets and enhancing its core competitiveness. As of the date of the announcement, the company has signed formal cooperation agreements covering dozens of countries overseas. The company will continue to promote the commercialization of its products in more countries, further increasing the global accessibility of the anti-TNF monoclonal antibody injections.